Portfolio Case
  • Managing director
    Xiaoxiao Peng Managing director
    ·Ph.D. at Karolinska Institutet.  
    ·

    Former Senior Scientist in AstraZeneca, Senior Associate in Department of Strategic Investment in a well-known listed company.  

    ·

    Overseas High-Level Talent of Shenzhen City Peacock Program.

    ·

    Has a few high impact publications in top journals such as Cell, Science Translational Medicine, Diabetes, Cell Death & Disease etc. Has insightful views to biopharma and biotech industry.


    [查看详情]
  • Deputy Managing Director
    Jianchuan Wang Deputy Managing Director
    ·

    Postdoctoral fellow of harvard medical school

    ·

    He has been a domestic and international investment consultant for new drugs, and has published many papers as the first author in well-known academic journals such as Nature






    [查看详情]
  • Managing director
    Ran Wang Managing director
    ·

    M.S. from University of Liverpool

    ·

    Got 10 Million+ investment from SBCVC for the company founded by her own

    ·

    Ever worked for Zero2Ipo Group's reaserach center. Rich experience and resources in investment business


    [查看详情]
  • Deputy Managing Director
    Hao Ye Deputy Managing Director

    ·B.S. in resource science and Engineering at South China University of Technology; MBA at China Resources University.
    ·Served as a manager at 999 pharmaceuticals and China resources financial group. 
    ·Over 10 years of experience in Pharmaceutical industry and finance. Managed a private equity fund of 5 billion RMB and help public companies with M&A. 





    [查看详情]
  • Principal
    Hao Li Principal
    ·Postdoctoral fellow at Stanford University.
    ·

    Former head of external innovation at Novartis; Won Novartis team innovation award twice. 

    ·

    Over 20 years of pharmaceutical industry experience.

    ·

    Has published numerous research papers on world renowned journals such as Cell, Development, Genome research and etc.


    [查看详情]
  • Principal
    Ning Lei Principal

    ·

    		M.D. at The West China College of Medicine; Ph.D. in Pharmaceutical Sciences at Sichuan University
    ·Over 10-years experiences in development and investment of medical device. 
    ·Part of the core research team of long-acting anti-AIDS drug “Albuvirtide” and diabetes AMD drug “Conbercept”. Rich experience in oversea CRO/Pharma/Biotech.

     

    [查看详情]
  • Deputy director of investment
    Li Hua Deputy director of investment
    ·Ph.D. in chemistry at University of Hong Kong with Ph.D. in Chemistry. CFA candidate.
    ·Served as the investment director in a domestic well-known Capital Management company; Participated in deal sourcing, due diligence and post-investment management.
    ·Worked in the investment banking department in National Gold Securities. She also participated in IPO industrial research, supplier development and profitability analysis.


    [查看详情]
  • Deputy director of investment
    Xinhao Zhao Deputy director of investment
    ·doctor of microbiology, Chinese academy of sciences.
    ·co-founder of kedi health.
    ·obtained RMB 12 million in financing for the company, and published an article in nature magazine.


    [查看详情]
  • Deputy director of investment
    Cherry Deputy director of investment
    ·

    Sun yat-sen university & kansai university, Japan

    ·

    Pharmaceutical molecular biology and financial complex background

    ·

    He used to work in domestic well-known medical investment machinery and industry






    [查看详情]
  • Investment manager
    Yaochun Xu Investment manager
    ·

    Doctor of pharmaceutical chemistry, university of Paris, France

    ·

    Previously worked in a well-known pharmaceutical research and development CRO/CDMO company, specializing in innovative drug research and development









    [查看详情]
  • Investment manager
    Yuxi Jiang Investment manager
    ·

    Shanghai jiao tong university pharmacy major bachelor minor law investment

    ·

    He used to be the investment manager of China finance and financial holding co., ltd. and China innovation investment co., LTD. He successfully invested in pharmaceutical projects such as Marine and biological projectsPreviously worked in a well-known pharmaceutical research and development CRO/CDMO company, specializing in innovative drug research and development











    [查看详情]
  • Senior Analyst
    Jiawei Zhang Senior Analyst
    ·

    Doctor of chemistry, university of Texas at Austin

    ·

    A founding partner of Replix Research Group, familiar with FDA rules and successfully excavated Viking, Zogenix, Corium, etc


    [查看详情]
  • Senior Analyst
    Jiaao Wei Senior Analyst
    ·

    PhD in biochemistry, CFA candidate, university of Oxford

    ·

    The doctoral entrepreneurship program I established once won the first prize of the national entrepreneurship competition. I once worked as an intern in a well-known domestic securities firm and deeply participated in the analysis of the pharmaceutical industry









    [查看详情]
  • Senior Analyst
    Yuewen Luo Senior Analyst
    ·

    Sun yat-sen university molecular medicine doctor

    ·

    He served as a postdoctoral researcher and assistant researcher in the school of medicine, sun yat-sen university, focusing on molecular immunology, tumor immunology, metabolomics and other fields





    [查看详情]
  • Senior Analyst
    Sylvia Li Senior Analyst
    ·

    BSc in Biomedical Science at Imperial College London

    ·

    MSc in Chinese University of Hong Kong


    [查看详情]
Home
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL：0755-8831-6141
E-mail：info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
粵ICP備09063742號-1
  Sitemap
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务